160 related articles for article (PubMed ID: 37952610)
21.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
22. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.
Billadeau D; Van Ness B; Kimlinger T; Kyle RA; Therneau TM; Greipp PR; Witzig TE
Blood; 1996 Jul; 88(1):289-96. PubMed ID: 8704185
[TBL] [Abstract][Full Text] [Related]
23. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.
Tomasson MH; Ali M; De Oliveira V; Xiao Q; Jethava Y; Zhan F; Fitzsimmons AM; Bates ML
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453544
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
27. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
28. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
29. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
Grass S; Preuss KD; Ahlgrimm M; Fadle N; Regitz E; Pfoehler C; Murawski N; Pfreundschuh M
Lancet Oncol; 2009 Oct; 10(10):950-6. PubMed ID: 19767238
[TBL] [Abstract][Full Text] [Related]
30. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
Walker BA; Wardell CP; Melchor L; Brioli A; Johnson DC; Kaiser MF; Mirabella F; Lopez-Corral L; Humphray S; Murray L; Ross M; Bentley D; Gutiérrez NC; Garcia-Sanz R; San Miguel J; Davies FE; Gonzalez D; Morgan GJ
Leukemia; 2014 Feb; 28(2):384-390. PubMed ID: 23817176
[TBL] [Abstract][Full Text] [Related]
31. Improving knowledge on the activation of bone marrow fibroblasts in MGUS and MM disease through the automatic extraction of genes via a nonnegative matrix factorization approach on gene expression profiles.
Boccarelli A; Esposito F; Coluccia M; Frassanito MA; Vacca A; Del Buono N
J Transl Med; 2018 Aug; 16(1):217. PubMed ID: 30075788
[TBL] [Abstract][Full Text] [Related]
32. The bone-marrow niche in MDS and MGUS: implications for AML and MM.
Ghobrial IM; Detappe A; Anderson KC; Steensma DP
Nat Rev Clin Oncol; 2018 Apr; 15(4):219-233. PubMed ID: 29311715
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
35. MGUS to myeloma: a mysterious gammopathy of underexplored significance.
Dhodapkar MV
Blood; 2016 Dec; 128(23):2599-2606. PubMed ID: 27737890
[TBL] [Abstract][Full Text] [Related]
36. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
37. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
38. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
39. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
